Overview

A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

Status:
Completed

Trial end date:
2021-08-05

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the clinical effectiveness and side effects of the vorinostat, bortezomib, lenalidomide, and dexamethasone investigational combination.

Phase:

Phase 1

Details

Lead Sponsor:

Emory University

Collaborators:

Celgene Corporation
Merck Sharp & Dohme Corp.

Treatments:

BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Lenalidomide
Thalidomide
Vorinostat